Navigation Links
Tumor cells seek temporary shelter from cancer drugs
Date:4/1/2010

Results reported in the April 2nd issue of the journal Cell, a Cell Press publication, reveal a new source for the drug resistance that crops up all too often and quickly in the tumors of cancer patients undergoing therapy. First the bad news: all cancer cells might have the capacity to enter a drug-tolerant state. But there's some potentially very good news too: in some cases there may be a way to reverse or block cancer's drug resistance.

"The problem with cancer drug therapy is that even the ones that work well generally only work for a limited time because drug resistance develops," said Jeff Settleman of Harvard's Massachusetts General Hospital Cancer Center.

Scientists have thought that resistance primarily stems from genetic causes mutations in some tumor cells that may have pre-existed drug treatment. The theory holds that those drug-resistant mutants rise in prevalence with treatment as a classic example of survival of the fittest. "We're suggesting here that, while that may occur, there may be other non-genetic mechanisms [for drug resistance] that serve as a way to protect the tumor as a whole in a somewhat purposeful way," Settleman added.

While examining the acute response of human tumor cells in culture to various anti-cancer agents, Settleman and his colleague Marie Classon consistently detected a small subpopulation of reversibly "drug-tolerant" cells. Those cells were more than 100 times less sensitive to cancer drugs. They also found that the cells' drug tolerant state was transiently acquired and relinquished at low frequency by individual cells within the culture population.

The researchers don't yet know exactly how the cells manage that kind of reversible drug resistance, but they did uncover a couple of key features: the cells engage a signaling pathway including the IGF-1 receptor (which is a tyrosine kinase receptor) and their genetic material was also packaged differently into its three-dimensional structure (known as chromatin). That altered chromatin state depends on a particular enzyme that chemically modifies the histone proteins that are often likened to spools for DNA.

The new results add to other recent work suggesting that drug resistance might not always have to arise through genetic mutation, Settleman said. For example, accumulating evidence suggests that a small population of "cancer stem cells" is intrinsically more difficult to treat.

A handful of other studies have also raised the possibility that epigenetic mechanisms like the one now described might be at play, the researchers note. This path to reversible drug resistance may explain an increasingly observed phenomenon in cancer therapy -- the so-called "re-treatment response" in which cancer patients who have grown resistant to a variety of anticancer drugs can be successfully re-treated with the same drug after a "drug holiday."

The new study also suggests a promising new kind of combination cancer therapy designed to avoid drug resistance or as secondary treatment for cancers that have already developed resistance to other drugs. Indeed, the researchers found that their drug-tolerant cells in culture could be killed by treating them with IGF-1 receptor blockers or chromatin-modifying agents. "It presents a therapeutic opportunity," Classon said.

In fact, the researchers say they've already launched a clinical trial in patients with lung cancer to test a combination therapy including a chromatin-modifying agent and the drug erlotinib, which is a tyrosine kinase inhibitor.

"Although the trial is not yet completed, the early clinical data indicate that the inclusion of a chromatin-modifying agent can dramatically improve clinical benefit in a subset of patients demonstrating acquired tyrosine kinase inhibitor resistance," the researchers wrote in conclusion. "When considering that acquired drug resistance may involve multiple distinct molecular mechanisms that arise independently within the same patient, thereby complicating strategies to overcome such resistance with a single rationally targeted agent, the potential ability to prevent the development of resistance by disrupting a drug-tolerant state is provocative. However, further studies will certainly be required to establish the in vivo significance of the cell culture findings, as well as to determine more precisely the molecular mechanisms underlying reversible drug tolerance."


'/>"/>

Contact: Cathleen Genova
cgenova@cell.com
617-397-2802
Cell Press
Source:Eurekalert

Related medicine news :

1. Researchers quantify benefits of minimally invasive removal of hard-to-reach tumors
2. Improved device provides more rapid, comprehensive analysis of circulating tumor cells
3. Protein in Breast Tumors May Predict Chemo Response
4. Tumors hide out from the immune system by mimicking lymph nodes
5. Chemo Plus Synthetic Drug Shrunk Pancreatic Tumors
6. Tumors Use a Protein to Hide From Immune System
7. Breast Cancers Return in Original Tumor Site a Bad Sign
8. Chemotherapy plus synthetic compound provides potent anti-tumor effect in pancreatic cancers
9. Miles for Hope’s Moving Towards A Cure(SM) Brain Tumor Walk in Boston Raising Funds for Brain Tumor Vaccine and Massachusetts General Hospital
10. Overcoming tumor resistance to anti-cancer agent TRAIL
11. Solid-pseudopapillary neoplasm of the pancreas or pancreatic endocrine tumor?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from ... at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center ... care topics including advance care planning, healthcare costs and patient and family engagement. ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... ... the United States, named Dr. Sesan Ogunleye, as the Medical Director of its new ... the facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the ... In terms of the latter, setting the bar too high can result in disappointment, ... just slow progress toward their goal. , Research from PsychTests.com reveals ...
(Date:6/24/2016)... ... ... crisis. Her son James, eight, was out of control. Prone to extreme mood shifts and ... him, he couldn’t control his emotions,” remembers Marcy. “If there was a knife on ... say he was going to kill them. If we were driving on the freeway, ...
(Date:6/24/2016)... ... 24, 2016 , ... Comfort Keepers® of San Diego, CA is excited to ... Recovery® program to drive cancer patients to and from their cancer treatments. Comfort ... quality of life and ongoing independence. Getting to and from medical treatments is ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... -- The Academy of Managed Care Pharmacy (AMCP) today ... allow biopharmaceutical companies to more easily share health care ... coverage decisions, a move that addresses the growing need ... The recommendations address restrictions in the sharing of product ... a prohibition that hinders decision makers from accessing HCEI ...
(Date:6/24/2016)... , June 24, 2016 Research ... World Market for Companion Diagnostic Tests" report to their ... Market for Companion Diagnostics The World Market ... and personalized medicine diagnostics. Market analysis in the report includes ... Test Market (In Vitro Diagnostic Kits) by Region (N. America, ...
(Date:6/24/2016)... Belgium , June 24, 2016 ... today announced the appointment of Dr. Edward ... as a Non-Executive Director, effective June 23, 2016.Dr. ... Compensation and Nominations and Governance Committees.  As a ... will provide independent expertise and strategic counsel to ...
Breaking Medicine Technology: